AdipoGen Life Sciences

anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free)

CHF 480.00

In stock

AG-27B-6002PF-C100100 µgCHF 480.00

More Information
Product Details
Synonyms	CD40 Ligand; CD154; Tumor Necrosis Factor Ligand Superfamily Member 5;TNFSF5; Gp39; TRAP
Product Type	Recombinant Antibody
Properties
Clone	hu5c8
Isotype	Human IgG1κ
Immunogen/Antigen	Recombinant human CD40L.
Label/Conjugates	Preservative Free
Application	Flow Cytometry: 1µg/ml Functional Application (Blocking): Neutralizes CD40L function by blocking the interaction between CD40 and CD40L in vitro and in vivo. Western Blot: 1µg/ml Optimal conditions should be determined individually for each application.
Crossreactivity	Dog Human
Specificity	Recognizes and binds human CD40L with an IC₅₀ of 0.845µg/ml. Cross-reacts with canine CD40L.
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein A-affinity purified.
Endotoxin Content	<0.001EU/μg
Concentration	1mg/ml
Formulation	Liquid. In PBS.
Isotype Negative Control	Human IgG1 Isotype Control (preservative free)
Other Product Data	This antibody is a biosimilar called Ruplizumab (Antova; BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.
Accession Number	UniProt ID P29965
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.

Product References

Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys: J.V Gobburu, et al.; JPET 286, 925 (1998)
Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates: A.D. Kirk, et al.; Nat. Med. 5, 686 (1999)
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154: N.S. Kenyon, et al.; PNAS 96, 8132 (1999)
Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154: N.S. Kenyon, et al.; Diabetes 48, 1473 (1999)
Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody: R.N. Pierson, et al.; Transplantation 68, 1800 (1999)
Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody: M. Karpusas, et al.; Structure 9, 321 (2001)
Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients: C.S. Cho, et al.; Transplantation 72, 587 (2001)
Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates: E.A. Elster, et al.; Transplantation 72, 1473 (2001)
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus: W. Huang, et al.; Arthr. Rheum. 46, 1554 (2002)
Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates: H. Xu, et al.; Transplantation 74, 940 (2002)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis: D.T. Boumpas, et al.; Arthr. Rheum. 48, 719 (2003)
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions: A.C. Grammer, et al.; J. Clin. Invest. 112, 1506 (2003)
Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade: M. Arpinati, et al.; Exp. Hematol. 31, 31 (2003)
CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation: C. Jochum, et al.; Biol. Blood Marrow. Transplant. 13, 164 (2007)
Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody: M. Arpinati, et al.; Eur. J. Haematol. 80, 322 (2008)
Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig: S.S. Graves, et al.; Transplantation 88, 317 (2009)

Call	+41 61 926 6040
Fax	+41 61 926 6049